Product Description
CDK3/CyclinE1 is a serine/threonine kinase complex composed of the catalytic subunit CDK3 (cyclin-dependent kinase 3) and the regulatory subunit Cyclin E1, which plays a pivotal role in cell cycle progression, specifically facilitating the transition from G0/G1 phase to S phase and promoting entry into DNA replication. The CDK3/CyclinE1 complex phosphorylates key substrates such as retinoblastoma protein (RB), thereby inactivating RB and enabling E2F-mediated transcription of genes required for S-phase progression. Beyond its essential physiological functions in cell cycle control and cellular quiescence exit, dysregulation of CDK3/CyclinE1 signaling—including overexpression, gene amplification, and aberrant activation—is frequently observed in various human cancers, such as breast, ovarian, and hepatocellular carcinoma, contributing to uncontrolled proliferation, genomic instability, and poor prognosis. These features have established CDK3/CyclinE1 as a highly validated target for cancer therapy and drug discovery.
Screeningbio’s CDK3/CyclinE1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CDK3/CyclinE1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: CDK3/CyclinE1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CDK3/CyclinE1 kinase.
Data